Recent Finacing
Recent Raise
Imvax is a clinical-stage biotech developing whole-tumor immunotherapies via its Goldspire platform; lead IGV-001 is an autologous biologic-device in a randomized double-blind Phase 2b trial for newly diagnosed glioblastoma.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
